EUVIMEDSkopri EUVIMED
Open access · CC BY 4.0

Engineered Chiral Probiotics Ameliorate MASH via Gut–Liver Axis

Jing Chen, Shen Zhang, Yuli Zhu iD, Da Zhou, Chunya Ji, Mingrui Zhu, Sirui Wang, Yuting Shen, Jifeng Yu, Heng Zhang iD, Yan Fang, Huixiong Xu iD and 1 more

Advanced Science · 2026-11-04

DOI: 10.1002/advs.78432 ↗

At a glance

Journal article in Advanced Science, published online on 2026-11-04. Written by Jing Chen and 12 co-authors. Institution: Department of Ultrasound, Zhongshan Hospital, Institute of Ultrasound in Medicine and Engineering, Fudan University, Shanghai, People's Republic of C…. 58 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Natural Science Foundation of China, National Key Research and Development Program of the Ministry of Science and Technology of China, Shanghai Municipal Health Commission.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

The global epidemic of metabolic dysfunction‐associated steatohepatitis (MASH) is escalating without effective therapies. This study identified a significant depletion of the gut commensal bacterium Faecalibacterium duncaniae ( F. duncaniae ) as a core feature of MASH. To overcome the poor colonization by traditional probiotics in inflammatory environments, we engineered a living microbial therapeutic by incorporating chiral gold nanozymes onto F. duncaniae . We discovered that biological performance is enantiomer‐dependent: the right‐handed nanozyme (D‐Au) serves as a superior ROS‐scavenging shield, protecting the probiotic from oxidative assault and enhancing its colonization in the inflamed gut. In mouse models of MASH, this engineered probiotic (F@D‐Au) reversed disease progression, ameliorating steatosis, inflammation, and fibrosis. It further restored systemic homeostasis, rectifying dysbiosis, metabolic disturbances, and—notably—MASH‐associated cognitive impairment. Metabolomic analyses revealed that this multi‐organ benefit was linked to the restoration of key microbial metabolites, including kynurenic acid and linoleic acid. Our work establishes a new class of chirality‐enhanced living therapeutics that precisely remodel the gut–liver axis, offering a transformative strategy for treating MASH and its complications.

Subjects

Author keywords

biologydysbiosisfibrosisinflammationkynurenic acidlinoleic acidmicrobiomeprobioticsteatohepatitisteatosis

Authors and institutions

  • Department of Ultrasound, Zhongshan Hospital, Institute of Ultrasound in Medicine and Engineering, Fudan University, Shanghai, People's Republic of China.
  • Department of Ultrasound, Zhuhai People's Hospital (The Affiliated Hospital of Beijing Institute of Technology, Zhuhai Clinical Medical College of Jinan University), Zhuhai, People's Republic of China.
  • Department of Gastroenterology, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.
  • Department of Ultrasound, Huashan Hospital, Fudan University, Shanghai, People's Republic of China.

ORCID profiles: Yuli Zhu, Heng Zhang, Huixiong Xu, Haohao Yin

Funding

  • National Natural Science Foundation of China
  • National Key Research and Development Program of the Ministry of Science and Technology of China
  • Shanghai Municipal Health Commission
  • Scientific Research and Development Fund of Zhongshan Hospital
  • Shanghai Sailing Program
  • China Postdoctoral Science Foundation

Cite

APA

Chen, J., Zhang, S., Zhu, Y., Zhou, D., Ji, C., Zhu, M., Wang, S., Shen, Y., Yu, J., Zhang, H., Fang, Y., Xu, H., & Yin, H. (2026). Engineered Chiral Probiotics Ameliorate MASH via Gut–Liver Axis. Advanced Science. https://doi.org/10.1002/advs.78432

Vancouver

Chen J, Zhang S, Zhu Y, Zhou D, Ji C, Zhu M, et al. Engineered Chiral Probiotics Ameliorate MASH via Gut–Liver Axis. Advanced Science. 2026. doi:10.1002/advs.78432

BibTeX
@article{Chen2026,
  author = {Chen, Jing and Zhang, Shen and Zhu, Yuli and Zhou, Da and Ji, Chunya and Zhu, Mingrui and Wang, Sirui and Shen, Yuting and Yu, Jifeng and Zhang, Heng and Fang, Yan and Xu, Huixiong and Yin, Haohao},
  title = {Engineered Chiral Probiotics Ameliorate MASH via Gut–Liver Axis},
  journal = {Advanced Science},
  year = {2026},
  doi = {10.1002/advs.78432}
}
Start for free →